Predicting hepatocellular carcinoma (HCC) development in chronic hepatitis B and chronic hepatitis C patients at risk by circulating miRNAs profiling.
|SPEAKER:||Dr Massimo Levrero|
Sep 22, 2020
|LOCATION:||Live webinar with Q&A|
Hepatocellular carcinoma (HCC) represents the fourth leading cause of cancer death with an increasing incidence around the world (GLOBOCAN: http://globocan.iarc.fr). Chronic infection with hepatitis B and C viruses (HBV, HCV), ethanol consumption and non-alcoholic fatty liver disease (NAFLD) account for >90% of HCCs. Treatment of the underlying cause (e.g. HCV eradication by direct-acting antivirals (DAAs) and HBV suppression by nucleos(t)ide analogs (NUCs)) decreases but does not eliminate HCC risk in patients with advanced fibrosis and established cirrhosis. New diagnostic biomarkers for risk stratification and early diagnosis are urgently needed to increase the access to curative therapeutic options. We describe here our experience on the profiling of serum miRNAs with the Nanostring technology to identify circulating miRNAs associated with a higher risk of developing HCC in HBV and HCV cirrhotic patients treated with direct acting antivirals that can be potentially integrated into existing clinical HCC prediction scores.